HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales Grow Across C&D's Products And Regions, But Increasing Supply Costs Stunt Income

Executive Summary

Raw material supplies slowed during January-March period by catastrophic freeze in Texas and shortage of shipping containers partly due to Suez Canal blockage. "We're absorbing $90 million of incremental costs for the full year,” says CFO Ronald Dierker.

You may also be interested in...



P&G Begins US Price Increases In Baby And Feminine Care, Could Expand To Health, Beauty

P&G plans up to double-digit price increases in US baby care, feminine care and adult incontinence and will analyze raw material costs and foreign exchange impacts in its other product categories for other pricing changes.

Church & Dwight Lifts Curtain On 2021: Halle Berry For Flawless, Vitafusion In Cough/Cold Aisle

Emerging markets expected to be growth drivers across C&D’s supplement, OTC drug and household care product lines in 2021. Super Immune formulation with more than 100% daily value of vitamin C, zinc and elderberry and Manuka honey is first vitafusion product in cough/cold aisle and brand's first extension for 2021.

Demand For Vitafusion, L’il Critters Gummy Lines Exceeds Church & Dwight Capacity, Drive Q3 Growth

Church & Dwight reports strong consumption of its Vitafusion and L’il Critters vitamins drove personal care product division sales up 24.5% and prompted it to use contract manufacturing to meet demand. The firm also adjusted its net sales outlook for the year to 11% and its EPS to $2.79-$2.81.

Topics

Related Companies

UsernamePublicRestriction

Register

RS151281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel